Abstract
Clinical use of various biological agents (protein-based products derived from biological sources, such as bacteria, fungi or mammalian cells) have greatly improved the treatment of a wide variety of diseases in humans. Nevertheless, a variety of their adverse reactions have been observed. These adverse effects have been clasified in five types (α, β, γ, δ and ε). Type β adverse effect involves hypersensitivity reactions linked to the immunogenicity of biological agents. It is worth emphasizing that biological agents irrespective whether they contain xenoantigens may lead to development of anti-drug antibodies. Several drug-, patients-, diseaseand treatment-related factors contribute to immunogenicity of biological agents. Anti-drug antibodies can influence either the efficacy of biological agent or induce hypersensitivity reactions. One of them is immediate infusion reaction, which occurs during or within one hour after biological agent infusion. This reaction may cause mild to severe clinical manifestations. Involvement of IgE- and non-IgE isotypes in hypersentitivity reactions are confirmed by novel methods for detecting anti-drug antibodies. This manuscript summarizes the current knowledge on factors influencing immunogenicity to biological agents, and points to the mechanisms underlying the drug-induced hypersensitivity reactions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
